Primecap Management Co. CA boosted its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 8.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,668,550 shares of the company's stock after purchasing an additional 196,530 shares during the quarter. Primecap Management Co. CA owned approximately 5.33% of Immunocore worth $78,722,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the stock. Wellington Management Group LLP increased its holdings in shares of Immunocore by 10.5% in the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company's stock valued at $219,430,000 after acquiring an additional 668,382 shares during the last quarter. Two Sigma Advisers LP increased its holdings in shares of Immunocore by 65.6% in the 3rd quarter. Two Sigma Advisers LP now owns 757,700 shares of the company's stock valued at $23,587,000 after acquiring an additional 300,200 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Immunocore by 25.0% in the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock valued at $17,007,000 after acquiring an additional 109,206 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Immunocore by 27.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 498,221 shares of the company's stock valued at $15,510,000 after acquiring an additional 107,656 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Immunocore by 7,437.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company's stock valued at $2,872,000 after acquiring an additional 91,033 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.
Immunocore Stock Performance
Immunocore stock traded down $0.62 during mid-day trading on Friday, reaching $29.81. 440,012 shares of the company were exchanged, compared to its average volume of 435,951. Immunocore Holdings plc has a twelve month low of $27.19 and a twelve month high of $66.00. The firm's 50-day simple moving average is $29.99 and its two-hundred day simple moving average is $31.16. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The firm has a market cap of $1.49 billion, a PE ratio of -31.38 and a beta of 0.79.
Analysts Set New Price Targets
A number of research firms have recently commented on IMCR. Morgan Stanley reiterated an "equal weight" rating and issued a $35.00 price objective on shares of Immunocore in a report on Friday, March 7th. Needham & Company LLC reissued a "buy" rating and issued a $71.00 target price on shares of Immunocore in a research report on Wednesday, March 12th. Finally, HC Wainwright reissued a "buy" rating and issued a $100.00 target price on shares of Immunocore in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $65.64.
Read Our Latest Stock Analysis on Immunocore
Insiders Place Their Bets
In other Immunocore news, Director Bros. Advisors Lp Baker purchased 807,338 shares of Immunocore stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the acquisition, the director now directly owns 2,144,060 shares of the company's stock, valued at $63,721,463.20. This represents a 60.40 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 9.10% of the stock is owned by insiders.
Immunocore Profile
(
Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Featured Stories
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
